A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study

Dimos D Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti, Panayiotis Mitsias, Dimos D Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti, Panayiotis Mitsias

Abstract

Introduction: The efficacy of prolonged-release fampridine (PR-FAM) may extend in multiple sclerosis (MS) beyond walking ability. The objective of this study was to evaluate the effect of PR-FAM treatment on cognition, fatigue, depression, and quality of life (QoL) in adult patients with MS in a real-world setting.

Methods: FAMILY was a multi-center, prospective, observational, real-world cohort study of MS patients receiving PR-FAM in the outpatient setting. Patients were treated as per PR-FAM's local prescribing information for 6 months. Standardized protocols and questionnaires were used to evaluate changes in cognition (PASAT; Paced Auditory Serial Addition Test), fatigue (MFIS; Modified Fatigue Impact Scale), depression (BDI-II; Beck Depression Inventory-II) and QoL (MusiQoL; MS International Quality-of-Life questionnaire, MSIS-29; Multiple Sclerosis Impact Scale: PHYS and PSYCH subscales) at 3 and 6 months compared to baseline.

Results: In total, 102 eligible patients from 8 sites in Greece were analysed, of whom 92 completed the study and 10 discontinued. At 6 months, PR-FAM treatment resulted in improvements from baseline in PASAT-3'' (p = 0.044), MFIS (p < 0.001), BDI-II (p < 0.001), MusiQoL (p < 0.001) and MSIS-29-PHYS (p = 0.012) and MSIS-PSYCH (p < 0.001). A positive effect was evident already at 3 months in PASAT-3'' (ns), MFIS (p = 0.020), BDI-II (p = 0.034), MusiQoL (p = 0.001), MSIS-29-PHYS (ns) and MSIS-29-PSYCH (p < 0.001).

Conclusions: This observational study provides new data to the current literature in support of PR-FAM's positive effects in cognition, fatigue, depression, and QoL in a large, heterogeneous group of Greek MS patients in the real-world setting.

Trial registration: ClinicalTrials.gov identifier, NCT03164018.

Keywords: Cognition; Depression; Fatigue; Multiple sclerosis; Neurology; PR-FAM; QoL; Walking ability.

Figures

Fig 1
Fig 1
Study flow chart

References

    1. Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, et al. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther. Adv. Neurol. Disord. 2018;11:1–8.
    1. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J. Neurol. Sci. 2009;277(S1):S37–41.
    1. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: The impact of depression, fatigue and disability. Mult Scler. 2001;7:340–344.
    1. Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, et al. Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. Ther Adv Chronic Dis. 2019;10:1–11.
    1. Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367–368.
    1. Lerdal A, Gulowsen Celius E, Krupp L, Dahl AA. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338–1343.
    1. Braley TJ, Chervin RD. Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment. Sleep [Internet]. 2010;33:1061–7. Available from: 10.1093/sleep/33.8.1061
    1. Tur C. Fatigue Management in Multiple Sclerosis. Curr. Treat. Options Neurol. 2016;18:26.
    1. Rosti E, Hämäläinen P, Koivisto K, Hokkanen L. PASAT in detecting cognitive impairment in relapsing-remitting MS. Appl Neuropsychol. 2007;14(2):101–112.
    1. Moccia M, Lanzillo R, Palladino R, Chang KCM, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–667.
    1. Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis [Internet]. Int. Rev. Psychiatry. Taylor and Francis Ltd; 2017;29(5):463–72. Available from: 10.1080/09540261.2017.1322555.
    1. Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. Neurology. 2019;93:1–8.
    1. Ysrraelit MC, Fiol MP, Gaitán MI, Correale J. Quality of life assessment in multiple sclerosis: Different perception between patients and neurologists. Front Neurol. 2018;8:729.
    1. Dunn J, Blight A. Dalfampridine: A brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr. Med. Res. Opin. 2011;27(7):1415–1423.
    1. EMA. Assessment Report; Fampyra [Internet]. 2011. Available from:
    1. EMA. Assessment Report; Fampyra [Internet]. 2017. Available from:
    1. Korsen M, Kunz R, Schminke U, Runge U, Kohlmann T, Dressel A. Dalfampridine effects on cognition, fatigue, and dexterity. Brain Behav. 2017;7(1):e0059.
    1. Broicher SD, Filli L, Geisseler O, Germann N, Zörner B, Brugger P, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol. 2018;265(5):1016–25.
    1. Triche EW, Ruiz JA, Olson KM, Lo AC. Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with dalfampridine-ER. Clin Neuropharmacol. 2016;39(2):73–80.
    1. Jacques F, Schembri A, Nativ A, Paquette C, Kalinowski P. Prolonged-release fampridine as adjunct therapy to active motor training in ms patients: a pilot, double-blind, randomized, placebo-controlled study. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318761168.
    1. Rodriguez-Leal FA, Haase R, Thomas K, Eisele JC, Proschmann U, Schultheiss T, et al. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Mult Scler J. 2018;24(10):1337–1346.
    1. Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61–79.
    1. Jensen HB, Nielsen JL, Ravnborg M, Dalgas U, Aagaard P, Stenager E. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137–144.
    1. Morrow SA, Rosehart H, Johnson AM. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord. 2017;11:4–9.
    1. Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7(6):354–8.
    1. Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, et al. Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci. 2014;337(1–2):18–24.
    1. Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35–40.
    1. Bakirtzis C, Konstantinopoulou E, Langdon DW, Grigoriadou E, Minti F, Nikolaidis I, et al. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS : The IGNITE study. J Neurol Sci. 2018;395:106–112.
    1. Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262(8):1936–45.
    1. Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager E. Changes in cognition, arm function and lower body function after slow-release fampridine treatment. Mult Scler J. 2014;20:1872–1880.
    1. Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, et al. Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler J. 2020;26(1):91–98.
    1. Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33(11):1087–1099.
    1. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5(4):244–250.
    1. Fischer JS, Jak AJ, Judith Kniker ME, Richard Rudick MA, Cutter G, Ellison G, et al. Administration and scoring manual manual prepared by administration and scoring manual. 2001
    1. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12) Neurology. 2003;60(1):31–6.
    1. Bakalidou D, Voumvourakis K, Tsourti Z, Papageorgiou E, Poulios A, Giannopoulos S. Validity and reliability of the Greek version of the Modified Fatigue Impact Scale in multiple sclerosis patients. Int J Rehabil Res. 2014;37(3):271–276.
    1. Miskovic A, Ehrlich-Jones L. Measurement characteristics and clinical utility of the modified fatigue impact scale in individuals with multiple sclerosis. Arch Phys Med Rehabil. 2018;97(7):1219–1220.
    1. Giannakou M, Roussi P, Kosmides ME, Kiosseoglou G, Adamopoulou A, Garyfallos G. Adaptation of the beck depression inventory-II to greek population. Hell J Psychol. 2013;10(2):120–146.
    1. Watson TM, Ford E, Worthington E, Lincoln NB. Validation of mood measures for people with multiple sclerosis. Int J MS Care. 2014;16(2):105–109.
    1. Triantafyllou N, Triantafillou A, Tsivgoulis G. Validity and reliability of the greek version of the multiple sclerosis international quality-of-life questionnaire. J Clin Neurol. 2009;5(4):173–177.
    1. Baumstarck K, Butzkueven H, Fernández O, Flachenecker P, Stecchi S, Idiman E, et al. Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health Qual Life Outcomes. 2013;11:127.
    1. Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al. The physical and psychological impact of multiple sclerosis using the MSIS-29 via the web portal of the UK MS register. PLoS One. 2013;8(1):e55422.
    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
    1. Ozakbas S, Yigit P, Cinar B. The effect of fampridine treatment on cognition: two year prospective study. Mult Scler J. 2017;23:412.
    1. De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, et al. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019;9:1–14.
    1. Foschi M, Lugaresi A. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? Expert Opin Pharmacother. 2019;20(11):1309–1320.
    1. Sumowski JF, Muhlert N. Dalfampridine improves slowed processing speed in MS: picking up the pace. Neurology. 2019;93(8):325.
    1. Rosti E, Hämäläinen P, Koivisto K, Hokkanen L. One-year follow-up study of relapsing-remitting MS patients’ cognitive performances: paced auditory serial addition test’s susceptibility to change. J Int Neuropsychol Soc [Internet]. 2007;13:791–8. Available from:
    1. Sagawa Y, Magnin E, Paillot L, Moulin T, Decavel P. Fampridine and quality of life in individuals with multiple sclerosis. Springerplus. 2016;5(1):1070.
    1. Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Front Neurol [Internet]. Frontiers Research Foundation; 2014;5:177. Available from:
    1. Gasperini C, Hupperts R, Lycke J, Short C, McNeill M, Zhong J, et al. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. J Neurol Sci. 2016;370:123–131. doi: 10.1016/j.jns.2016.08.052.
    1. Nagels G, Macdonell R, Soelberg Sorensen P, Pozzilli C, Laplaud D, de Jong B, et al. Long-Term Prolonged-Release Fampridine Treatment and Health-Related Quality of Life Outcomes: Interim Results of the Enable Study. Value Heal. 2013;16(7):627.
    1. Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;16:1509–1517.
    1. Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies A clinical point of view. Approaches and methodologies. Pulm. Pharmacol. Ther. 2014;27(2):129–138. doi: 10.1016/j.pupt.2014.01.005.
    1. Mahajan R. Real world data: Additional source for making clinical decisions. Int J Appl Basic Med Res. 2015;5(2):82. doi: 10.4103/2229-516X.157148.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel